Search research articles
Contact Us
Filters
Showing results (151-160 of 154) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 154 results.
American Journal of Medical Genetics
|
July 26, 1996
High phenotypic correlations among siblings with autism and pervasive developmental disorders
P Szatmari, M B Jones, J Holden, et al.
The American Journal of Psychiatry
|
August 1, 1989
The UCLA-University of Utah epidemiologic survey of autism: recurrence risk estimates and genetic counseling
E R Ritvo, L B Jorde, A Mason-Brothers, et al.
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity
|
April 22, 2003
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII
S C Benoit, R J Sheldon, E L Air, et al.
British Journal of Cancer
|
October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
I Brana, R Berger, T Golan, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 154) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 154 results.
American Journal of Medical Genetics
|
July 26, 1996
High phenotypic correlations among siblings with autism and pervasive developmental disorders
P Szatmari, M B Jones, J Holden, et al.
The American Journal of Psychiatry
|
August 1, 1989
The UCLA-University of Utah epidemiologic survey of autism: recurrence risk estimates and genetic counseling
E R Ritvo, L B Jorde, A Mason-Brothers, et al.
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity
|
April 22, 2003
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII
S C Benoit, R J Sheldon, E L Air, et al.
British Journal of Cancer
|
October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
I Brana, R Berger, T Golan, et al.
Page
of 16